GPC Biotech presents data on 1D09C3 anticancer monoclonal antibody.
The data reported demonstrate that 1D09C3 selectively induces programmed cell death (apoptosis) in a variety of xenotransplant lymphoid tumor models, including non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, and hairy cell leukemia, as well as new data in Burkitt's lymphoma.
"Our 1D09C3 monoclonal antibody has made solid progress in the past year," said Marcel Rozencweig, M.D., Senior Vice President, Drug Development. "We have recently completed pre-clinical testing with the antibody and are preparing to provide the necessary information to regulatory authorities and ethics committees to begin our first-in-man studies. Assuming that we receive the authorizations in a timely manner, we expect to initiate a Phase I study in B-cell lymphomas in Europe in the near future."
1D09C3 is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. This antibody binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. In 2003, it was estimated that more than 150,000 people in the developed world were diagnosed with non-Hodgkin's lymphoma -- the most common form of lymphoma -- with approximately one third of these patients in Europe and one third in the United States 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its therapeutic effect. Since most lymphoma patients are immunocompromised as a result of prior chemotherapy or the disease itself, this is potentially a significant advantage over most antibodies targeting B-cell lymphomas. Additionally, when 1D09C3 was administered with the anticancer drug, Rituxan (rituximab), in an in vivo NHL model, the efficacy was shown to be greater than with either antibody alone. The company expects to enter 1D09C3 into human clinical trials in the near future.
GPC Biotech is a biotechnology company discovering and developing new anticancer drugs. The company's lead product candidate - satraplatin - is currently in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer following successful completion of a Special Protocol Assessment by the United States FDA and receipt of a Scientific Advice letter from the European regulatory authority, EMEA. The FDA has also granted fast track designation to satraplatin for this indication. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. Other anticancer programs in development include a monoclonal antibody and a cell cycle inhibitor. The company is leveraging its drug discovery technologies to elucidate the mechanisms-of-action of drug candidates and to support the growth of its drug pipeline. The company has formed successful alliances with a number of pharmaceutical and biotechnology firms. For example, the company has a multi-year alliance with ALTANA Pharma AG to establish the ALTANA Research Institute in the United States, which provides GPC Biotech with revenues until 2007.
GPC Biotech AG